Navamedic ASA is a Nordic pharmaceutical company headquartered in Oslo, Norway, specializing in the supply of high-quality prescription drugs, consumer health products, and medical nutrition to hospit... Navamedic ASA is a Nordic pharmaceutical company headquartered in Oslo, Norway, specializing in the supply of high-quality prescription drugs, consumer health products, and medical nutrition to hospitals and pharmacies. Incorporated in 2002 and listed on the Oslo Stock Exchange since 2006, it focuses on addressing key public health challenges including obesity, Parkinson’s disease, antibiotics, addiction treatment, metabolism, cardiology, urology, and women’s health. The company operates across the Nordic countries—Norway, Sweden, Denmark, and Finland—along with the Benelux region, the Baltics, the UK, and Greece, employing around 42 professionals. Navamedic’s portfolio features both Rx and OTC pharmaceuticals, medical devices, food supplements, and cosmetics, sourced through strategic distribution agreements and in-licensing deals. Notable recent developments include the acquisition of the dne pharma business in 2025, bolstering its addiction treatment offerings, and innovations like advanced Parkinson’s care solutions for personalized dosing. With sales reaching 531 million NOK in 2024 and ambitions for further growth toward 1 billion NOK in revenues, Navamedic plays a vital role as a preferred partner for international firms entering Northern European markets, leveraging local expertise for regulatory compliance and market access.
Energy Management data not yet covered for Navamedic
We have not yet reviewed Navamedic's disclosures for Energy Management data.
If this data is relevant to your work, you can submit a data coverage request and our team
will investigate the company's disclosures and capture the data if available.